Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study.

Francesco SchettiniNavid SobhaniAnna IanzaTiziana TriulziAlfredo MolteniMaria Chiara LazzariCarla StrinaManuela MilaniSilvia Paola CoronaMarianna SiricoOttavia BernocchiFabiola GiudiciMaria Rosaria CappellettiEva CiruelosGuy JerusalemSherine LoiStephen B FoxDaniele Generali

Published in: Breast cancer research and treatment (2020)

Lymphocytes subpopulations, CECs and NLR could be interesting biomarkers predictive of response to everolimus-based regimens, potentially useful in daily clinical practice to select/monitor everolimus-based treatment in mBC. Further studies to confirm such hypotheses are warranted.

Keyphrases

positive breast cancer
clinical practice
combination therapy
risk assessment
smoking cessation